Wednesday, January 23, 2019

Lupin gets USFDA nod to market hypothyroidism treatment drug


Drug firm Lupin said it had received approval from the U.S. health regulator to market Levothyroxine Sodium tablets used for treating hypothyroidism. The company has received the USFDA’s approval to market the tablets in the strengths of 25 microgram (mcg), 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, and 300 mcg, Lupin said.

Source: THE HINDU-22nd January,2019